Socioeconomic Inequality in Respiratory Health in the US From 1959 to 2018.


Journal

JAMA internal medicine
ISSN: 2168-6114
Titre abrégé: JAMA Intern Med
Pays: United States
ID NLM: 101589534

Informations de publication

Date de publication:
01 07 2021
Historique:
pubmed: 29 5 2021
medline: 20 1 2022
entrez: 28 5 2021
Statut: ppublish

Résumé

Air quality has improved and smoking rates have declined over the past half-century in the US. It is unknown whether such secular improvements, and other policies, have helped close socioeconomic gaps in respiratory health. To describe long-term trends in socioeconomic disparities in respiratory disease prevalence, pulmonary symptoms, and pulmonary function. This repeated cross-sectional analysis of the nationally representative National Health and Nutrition Examination Surveys (NHANES) and predecessor surveys, conducted from 1959 to 2018. included 160 495 participants aged 6 to 74 years. Family income quintile defined using year-specific thresholds; educational attainment. Trends in socioeconomic disparities in prevalence of current/former smoking among adults aged 25 to 74 years; 3 respiratory symptoms (dyspnea on exertion, cough, and wheezing) among adults aged 40 to 74 years; asthma stratified by age (6-11, 12-17, and 18-74 years); chronic obstructive pulmonary disease ([COPD] adults aged 40-74 years); and 3 measures of pulmonary function (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC], and FEV1/FVC<0.70) among adults aged 24 to 74 years. Our sample included 160 495 individuals surveyed between 1959 and 2018: 27 948 children aged 6 to 11 years; 26 956 children aged 12 to 17 years; and 105 591 adults aged 18 to 74 years. Income- and education-based disparities in smoking prevalence widened from 1971 to 2018. Socioeconomic disparities in respiratory symptoms persisted or worsened from 1959 to 2018. For instance, from 1971 to 1975, 44.5% of those in the lowest income quintile reported dyspnea on exertion vs 26.4% of those in the highest quintile, whereas from 2017 to 2018 the corresponding proportions were 48.3% and 27.9%. Disparities in cough and wheezing rose over time. Asthma prevalence rose for all children after 1980, but more sharply among poorer children. Income-based disparities in diagnosed COPD also widened over time, from 4.5 percentage points (age- and sex-adjusted) in 1971 to 11.3 percentage points from 2013 to 2018. Socioeconomic disparities in FEV1 and FVC also increased. For instance, from 1971 to 1975, the age- and height-adjusted FEV1 of men in the lowest income quintile was 203.6 mL lower than men in the highest quintile, a difference that widened to 248.5 mL from 2007 to 2012 (95% CI, -328.0 to -169.0). However, disparities in rates of FEV1/FVC lower than 0.70 changed little. Socioeconomic disparities in pulmonary health persisted and potentially worsened over the past 6 decades, suggesting that the benefits of improved air quality and smoking reductions have not been equally distributed. Socioeconomic position may function as an independent determinant of pulmonary health.

Identifiants

pubmed: 34047754
pii: 2780281
doi: 10.1001/jamainternmed.2021.2441
pmc: PMC8261605
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

968-976

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Références

Chest. 2009 Oct;136(4):1063-1071
pubmed: 19567492
J Epidemiol Community Health. 2013 Nov 1;67(11):905-11
pubmed: 23929618
Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15078-83
pubmed: 26575631
J Allergy Clin Immunol. 2015 Mar;135(3):655-62
pubmed: 25617226
Environ Health Perspect. 2003 Dec;111(16):1861-70
pubmed: 14644658
J Asthma. 2013 Jun;50(5):488-96
pubmed: 23544662
N Engl J Med. 2017 Jun 29;376(26):2513-2522
pubmed: 28657878
Am J Epidemiol. 2010 Dec 15;172(12):1415-23
pubmed: 20961971
Thorax. 2003 May;58(5):388-93
pubmed: 12728157
Respir Med. 2007 Nov;101(11):2289-96
pubmed: 17681463
J Rural Health. 2022 Jan;38(1):207-216
pubmed: 33040358
J Asthma. 2020 May;57(5):510-520
pubmed: 30958048
Eur Respir J. 2008 Feb;31(2):416-69
pubmed: 18238951
Chest. 2021 Jun;159(6):2173-2182
pubmed: 33497651
BMJ. 1989 Aug 5;299(6695):357-61
pubmed: 2506967
N Engl J Med. 2006 Nov 23;355(21):2226-35
pubmed: 17124020
Am J Respir Crit Care Med. 2017 May 15;195(10):1399-1401
pubmed: 28504596
Int J Chron Obstruct Pulmon Dis. 2016 Oct 04;11:2475-2496
pubmed: 27785005
Am J Public Health. 2015 Jun;105(6):1269-75
pubmed: 25320897
Int J Health Serv. 2006;36(1):25-50
pubmed: 16524164
BMJ Open. 2019 Jun 20;9(6):e027528
pubmed: 31227536
Ann Am Thorac Soc. 2020 Jan;17(1):49-56
pubmed: 31599647
Am J Public Health. 1986 Nov;76(11):1308-11
pubmed: 3766826
Pediatrics. 2009 Mar;123 Suppl 3:S131-45
pubmed: 19221156
Tob Control. 2020 May;29(3):269-276
pubmed: 31147473
Health Qual Life Outcomes. 2010 Sep 27;8:107
pubmed: 20875099
Am J Ind Med. 2014 May;57(5):596-604
pubmed: 24375809
MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):693-698
pubmed: 32525855
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14911-14917
pubmed: 32541023
Annu Rev Public Health. 2005;26:89-113
pubmed: 15760282
J Health Soc Behav. 1995;Spec No:80-94
pubmed: 7560851
Ann Am Thorac Soc. 2014 Oct;11(8):1195-202
pubmed: 25166428
Int J Epidemiol. 2014 Aug;43(4):1294-313
pubmed: 24639440
JAMA. 2017 Sep 26;318(12):1136-1149
pubmed: 28973621
Chest. 2013 May;143(5):1395-1406
pubmed: 23715520
MMWR CDC Surveill Summ. 1998 Apr 24;47(1):1-27
pubmed: 9580746
Toxicol Ind Health. 1993 Sep-Oct;9(5):843-78
pubmed: 8184446
Lancet Glob Health. 2019 May;7(5):e613-e623
pubmed: 31000131
JAMA. 2016 Apr 26;315(16):1750-66
pubmed: 27063997
Pediatrics. 2016 Jan;137(1):
pubmed: 26712860
BMC Public Health. 2016 Feb 01;16:96
pubmed: 26832923
Am J Epidemiol. 2003 Jul 15;158(2):99-104
pubmed: 12851220
Chest. 2007 Nov;132(5):1608-14
pubmed: 17998360
Am J Respir Crit Care Med. 2011 Sep 1;184(5):521-7
pubmed: 21562132
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1575-1577
pubmed: 30917289

Auteurs

Adam W Gaffney (AW)

Cambridge Health Alliance, Cambridge, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

David U Himmelstein (DU)

Cambridge Health Alliance, Cambridge, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
City University of New York at Hunter College, New York.

David C Christiani (DC)

Harvard Medical School, Boston, Massachusetts.
Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Steffie Woolhandler (S)

Cambridge Health Alliance, Cambridge, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
City University of New York at Hunter College, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH